The initial reaction by Pfizer investors wasn’t that much more rapturous. Immediately after the announcement on Monday, Pfizer’s shares dropped 2.6% to trade at $31.33, while Allergan (technically the acquirer) saw its stock drop 3.4% to $301.72 a share, trading at 17% below the price that Allergan investors will get…